MRIdian is the world’s first MR-guided system used to clinically treat patients. Since January 2014, MRIdian has treated more than 2000 patients and delivered nearly 3000 on-table adapted fractions.
Today, MRIdian has been recognized and studied in more than 35 peer-reviewed publications, more than 50 journal abstracts, and more than 160 society papers and posters. Click to request ViewRay’s Clinical Bibliography.
MRIdian is currently the focus of numerous ongoing clinical trials spanning diverse indications including pancreas, breast, lung, and other cancers.